ReviewClinical and experimental hepatology2025
Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice.
Review in Clinical and experimental hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B.Annals of medicine · 2026Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of patients whose chronic metabolic liver disease leads to the development of hepatocellular carcinoma (HCC) is increasing. In patients with non-alcoholic fatty liver disease (NAFLD), HCC can arise in both cirrhotic and non-cirrhotic livers. This complicates appropriate surveillance and causes HCC to be diagnosed at a more advanced stage. Current therapeutic guidelines do not take into account the etiology of HCC when selecting the type of systemic treatment, as the data on the effectiveness of immunotherapy in HCC caused by metabolic dysfunction-associated steatotic liver disease (MASLD) are insufficient and come from post-hoc subgroup analysis in phase 3 trials. In order to improve survival in the group of patients with chronic liver disease and metabolic disorders, it is crucial to use non-pharmacological and pharmacological methods to prevent progression of fatty liver disease, treat comorbidities with modification of cardiometabolic risk factors, and implement effective programs for early detection of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.